⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4550206 | 1.00 | — | — | |
| SCHEMBL18800982 | 1.00 | — | — | |
| SCHEMBL16864296 | 0.75 | — | — | |
| SCHEMBL4717617 | 0.69 | — | — | |
| SCHEMBL9906472 | 0.69 | — | — | |
| SCHEMBL12848823 | 0.69 | — | — | |
| Cycloserine SCHEMBL8681117 | 0.68 | BLM (1.00) | — | |
| Cycloserine SCHEMBL8681114 | 0.68 | BLM (1.00) | — | |
| Cycloserine SCHEMBL34323 | 0.68 | — | — | |
| Cycloserine SCHEMBL6571320 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218638-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-07-13 | — | — | US | disclosed |
| WO-2021136354-A1 | BIPHENYL DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2021-07-08 | — | — | WO | disclosed |
| US-20170304321-A1 | NEUROACTIVE COMPOUNDS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS INC (US) | 2017-10-26 | — | — | US | disclosed |
| US-8871794-B2 | Small-molecule agonists for type-2 orexin receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140051700-A1 | Small-molecule agonists for type-2 orexin receptor | UNIVERSITY OF TEXAS, BOARD OF REGENTS | 2014-02-20 | — | — | US | disclosed |
| US-20120322761-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2012-12-20 | — | — | US | disclosed |
| US-8258163-B2 | Small-molecule agonists for type-2 orexin receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2012-09-04 | — | — | US | disclosed |
| EP-1954668-B9 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2012-03-21 | — | — | EP | disclosed |
| EP-1954668-B1 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2011-09-28 | — | — | EP | disclosed |
| US-20110224212-A1 | KINASE INHIBITOR COMPOUNDS | TYROGENEX, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110178079-A1 | GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | TAKTIX CORPORATION | 2011-07-21 | — | — | US | disclosed |
| US-20110166181-A1 | GUANIDINE COMPOUNDS AS ANESTHETICS AND FOR TREATMENT OF NERVOUS SYSTEM DISORDERS | TAKTIX CORPORATION | 2011-07-07 | — | — | US | disclosed |
| US-7888376-B2 | Cholesteryl ester transfer protein (CETP) inhibitors; atherosclerosis and cardiovascular diseases; N-(1-(5-chloropyridin-2-yl)-1-(3-fluoro-5-(trifluoromethyl)phenyl)-2-phenylethyl)-4-(trifluoromethyl)thiazol-2-amine; Alzheimer's, atherosclerosis, venous thrombosis, peripheral vascular disease | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-15 | — | — | US | disclosed |
| US-7868028-B2 | Guanidine compounds as anesthetics and for treatment of nervous system disorders | Drasner, Fred (US) | 2011-01-11 | — | — | US | disclosed |
| US-20100150840-A1 | Small-molecule agonists for type-2 orexin receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2010-06-17 | — | — | US | disclosed |
| US-20070161685-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-07-12 | — | — | US | disclosed |
| US-20070135631-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| WO-2007062314-A2 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007062308-A2 | HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-05-31 | — | — | WO | disclosed |